What type of study is this?

This is a Retrospective Study study.

September 10, 2025

Molecular tumor board-guided personalized therapies in biliary tract cancer: a real-world analysis

Key Points

Inclusion of molecular tumor boards significantly enhances personalized treatment strategies for biliary tract cancer.
Patients with intrahepatic cholangiocarcinoma showed up to 40% actionable targets for therapies.
This retrospective analysis assesses the implementation of recommended targeted therapies based on MTB recommendations.
Timely MTB referrals may improve outcomes for patients since only 20% achieve a five-year survival rate.

Abstract

Introduction: Biliary tract cancer (BTC) represents a major cause of cancer-related mortality worldwide, with a 5-year survival rate of less than 20%. Notably, distinct BTC subtypes, particularly intrahepatic cholangiocarcinoma, exhibit up to 40% actionable targets. This underscores the importance of an early referral to a Molecular Tumor Board (MTB) for the development of individualized, molecular guided therapeutic strategies. This retrospective study aims to evaluate the impact of MTB inclusion, recommended targeted therapies and their subsequent implementation in patients with BTC in a real-world setting.

Bookmark

Cite This Study

Barsch et al. (Mon,) studied this question.

synapsesocial.com/papers/68c194029b7b07f3a06186ef https://doi.org/https://doi.org/10.1055/s-0045-1810969

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark